BTG applies high quality development capabilities and substantial resources in the development of our programmes. We routinely review and determine the best development and commercialisation strategy for each asset, undertaking the development alone or in collaboration if we believe that would enhance the product’s value.

BTG's philosophy is to remain flexible in our approach to deal making. For details of potential partnering opportunities, please refer to our development pipeline.

We also have a number of other programmes that have completed preclinical or clinical studies and are available for partnering.

Plevitrexed (BGC 9331)
Gastric, pancreatic, ovarian cancer

KTX0101
Neuroprotection, epilepsy

BGC 945
Solid tumours

BGC20-0761
Antipsychotic with cognition improvement